Curve Therapeutics strengthens Leadership Team with appointment of experienced biotech executive Simon Jones

Accomplished CFO and COO with proven track record in the biotech and pharmaceutical industry Strengthens Curve’s Leadership Team following £40.5 million Series A financing Southampton, UK, 9 July 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the […]

Read more

Research published in Journal of the American Chemical Society highlights potential of HIF Inhibition as a therapeutic approach for cancers

Research led by Curve CSO Professor Ali Tavassoli’s laboratory at University of Southampton Landmark paper on dual HIF-1 and HIF-2 inhibitor that works by inhibiting the interaction of both HIF-1α and HIF-2α with HIF-1β Southampton, UK, 26 March 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening […]

Read more

Curve Therapeutics April 2024 Conference Attendance

Southampton, UK, 21 March 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces activity at the following scientific and investor conferences during April 2024. Anglonordic Life Science Conference, London, United Kingdom 18 April 2024 Attending: Simon Kerry, Chief […]

Read more

Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline

Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the close of its successful £40.5 million Series A financing. Pfizer Ventures led the round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and co-lead from the seed round, Epidarex Capital.

Read more

Curve Therapeutics appoints Dr Sally Price as Vice President of Biology

Dr Price brings over 20 years of experience in drug discovery and development, across pharma and biotech Southampton, UK, 18 September 2023 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a game-changing, functional drug discovery platform, today announces the appointment of Dr Sally Price as its Vice President of Biology. Dr […]

Read more

Curve Therapeutics Expands Leadership Team and Scientific Advisory Board: Dr Monika Ermann appointed Vice President Drug Discovery to advance Curve’s therapeutic programmes directed at challenging cancer targets

Dr Monika Ermann appointed Vice President Drug Discovery to advance Curve’s therapeutic programmes directed at challenging cancer targets Julian Downward (Francis Crick Institute) and Prof. Steven Benkovic (Penn State University) join the Scientific Advisory Board Relocation to bespoke laboratories and offices at Southampton Science Park Southampton, UK, 2 May 2023 – Curve Therapeutics (Curve), a […]

Read more

Curve CSO featured in the “Careers in Drug Discovery” podcast

Our CSO, Prof Ali Tavassoli, discusses his career, academic research and experience with building a Biotech company with Tom Froggatt in the “Careers in Drug Discovery” podcast. Listen to Ali and Tom’s conversation on iTunes or Spotify.

Read more

Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform

Curve’s innovative mammalian cell drug discovery platform to enable identification and optimisation of novel small molecule drug candidates against MSD targets Potentially game-changing platform enables direct discovery of functionally active molecules against difficult to drug targets expressed in their native intracellular environment Southampton, UK, 16th February 2022: Curve Therapeutics (Curve), a private biotechnology company pioneering […]

Read more

Curve Therapeutics Participates in Parliamentary Meetings

Southampton, UK, 31st July 2019. Curve Therapeutics (Curve) a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today announces its participation in the UK BioIndustry Association’s 2021 Parliament Day. This annual event gives senior representatives from the UK biotech sector the opportunity to meet with MPs, Ministers and Peers to discuss key […]

Read more

Curve Therapeutics Announces Grant of US Patent

Southampton, UK, 31st March 2021. Curve Therapeutics (Curve) a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today announces the grant of US Patent 10,962,549 describing novel Microcycles that inhibit both HIF-1 and HIF-2. Curve originated from world-leading Microcycle® research conducted by Professor Tavassoli’s group in the Department of Chemistry at the […]

Read more